Nutex Health (NASDAQ:NUTX) Upgraded by Wall Street Zen to "Buy" Rating

Key Points

• Wall Street Zen upgraded Nutex Health from hold to buy, while Weiss Ratings also nudged its rating higher, leaving the stock with an overall Moderate Buy consensus and an average price target of $252.50.
• The stock was up 1.5% and opened at $136.66, trading below its 12-month high of $193.07 but above its 50-day and 200-day moving averages.
• Nutex Health recently reported earnings per share of $6.52, beating estimates, though revenue of $216.49 million came in below expectations.

Nutex Health (NASDAQ:NUTX - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a report issued on Saturday.

Separately, Weiss Ratings raised shares of Nutex Health from a "hold (c)" rating to a "hold (c+)" rating in a report on Monday. Two equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, Nutex Health presently has an average rating of "Moderate Buy" and an average price target of $252.50.

Nutex Health Stock Up 1.5%

NUTX opened at $136.66 on Friday. The firm's 50-day simple moving average is $103.89 and its 200-day simple moving average is $127.27. The company has a debt-to-equity ratio of 0.66, a quick ratio of 3.39 and a current ratio of 3.14. Nutex Health has a twelve month low of $77.21 and a twelve month high of $193.07. The firm has a market cap of $940.22 million, a price-to-earnings ratio of 10.56 and a beta of 0.25.

Nutex Health (NASDAQ:NUTX - Get Free Report) last posted its earnings results on Thursday, April 30th. The company reported $6.52 earnings per share for the quarter, topping the consensus estimate of $3.99 by $2.53. Nutex Health had a net margin of 10.95% and a return on equity of 23.50%. The business had revenue of $216.49 million for the quarter, compared to analyst estimates of $227.80 million.

Institutional Investors Weigh In On Nutex Health

A number of hedge funds have recently added to or reduced their stakes in the stock. Deutsche Bank AG grew its holdings in Nutex Health by 3.9% during the 4th quarter. Deutsche Bank AG now owns 2,633 shares of the company's stock worth $433,000 after acquiring an additional 98 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in Nutex Health by 1.4% during the 4th quarter. Russell Investments Group Ltd. now owns 8,706 shares of the company's stock worth $1,433,000 after acquiring an additional 116 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al grew its holdings in Nutex Health by 3.7% during the 4th quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 5,600 shares of the company's stock worth $922,000 after acquiring an additional 200 shares during the last quarter. Islay Capital Management LLC bought a new stake in Nutex Health during the 4th quarter worth about $34,000. Finally, First Trust Advisors LP grew its holdings in Nutex Health by 2.4% during the 4th quarter. First Trust Advisors LP now owns 11,461 shares of the company's stock worth $1,887,000 after acquiring an additional 272 shares during the last quarter. Institutional investors own 5.32% of the company's stock.

About Nutex Health

Nutex Health, Inc NASDAQ: NUTX is an integrated outpatient healthcare services company based in San Antonio, Texas. The company focuses on delivering a range of ambulatory care solutions, including urgent care, telemedicine, medical imaging, teleradiology, weight‐loss services and behavioral health support. By combining in‐person clinics with virtual care capabilities, Nutex Health aims to provide patients with accessible, cost‐effective treatment options outside traditional hospital settings.

The company’s urgent care network operates through both standalone and retail‐anchored centers, offering treatment for non‐life‐threatening injuries and illnesses, preventive screenings and basic primary care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.